NCT01672853已完成2 期
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 235
- 试验地点
- 148
- 主要终点
- Change From Baseline in MQC on Liver Biopsy at Week 96
研究概览
简要总结
The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult Individuals (aged 18-70) with chronic cholestatic liver disease of at least 6 months.
- •Liver biopsy consistent with PSC: If a liver biopsy has been performed within 3 months of the screening visit, tissue from that biopsy may be used as the screening biopsy. Slides would be re-cut from the existing tissue block and submitted for central reader assessment. Some individuals with PSC may have a normal liver biopsy, in the event of a normal liver biopsy, the individual must have an abnormal magnetic resonance cholangiopancreatography (MRCP).
- •MRCP consistent with PSC: Some individuals with PSC may have a normal MRCP; in the event of a normal MRCP, the individual must have an abnormal liver biopsy.
- •Exclusion of other causes of liver disease including viral hepatitis ,alcoholic liver disease,primary biliary cirrhosis and secondary sclerosing cholangitis
- •Must have aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 10 x the Central Laboratory Upper Limit of Normal (clULN)
- •Must have serum creatinine < 2.0 mg/dL
- •A negative serum pregnancy test is required for female individuals of childbearing potential
- •All sexually active female individuals of childbearing potential must agree to use a protocol recommended method of contraception during heterosexual intercourse throughout the study and for 90 days following the last dose of study medication
- •Lactating females must agree to discontinue nursing before starting study treatment
- •Males if not vasectomized, are required to use barrier contraception (condom plus spermicide) during intercourse from the screening through the study completion and for 90 days following the last dose of study drug
排除标准
- •Pregnant or breast feeding
- •Evidence of hepatic decompensation present, including ascites, episodes of hepatic encephalopathy, variceal bleeding or a prolonged prothrombin time/international normalized ratio (PT/INR)
- •Positive for hepatitis C virus (HCV) RNA
- •Positive for HBsAg
- •Positive for anti-mitochondrial antibody
- •Alcohol consumption greater than 21oz/week for males or 14oz/week for females
- •Moderately active ulcerative colitis (UC) defined as either a partial Mayo score of > 4, bleeding score of >1, or current use of oral corticosteroid therapy and/or any inhibitor of Tumor necrosis factor-α (TNF-α) or α4β7 integrin antagonist
- •Positive urine screen for amphetamines, cocaine or opiates (i.e. heroin, morphine) at screening. Individuals on stable methadone or buprenorphine maintenance treatment for at least 6 months prior to screening may be included in the study. Individuals with a positive urine drug screen due to prescription opioid-based medication are eligible if the prescription and diagnosis are reviewed and approved by the investigator
- •Clinically significant cardiac disease
- •History of cholangiocarcinoma
- •History of other cancers,other than non-melanomatous skin cancer, within 5 years prior to screening
- •Ascending cholangitis within 60 days of screening
- •Presence of a percutaneous drain or bile duct stent
- •Known hypersensitivity to the investigation product or any of its formulation excipients
- •History of bleeding diathesis within 6 months of screening
- •Unavailable for follow-up assessment or concern for individual's compliance with the protocol procedures;
- •Participation in an investigational trial of a drug or device within 30 days prior to screening
- •Major surgical procedure within 30 days prior to screening or the presence of an open wound
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Treatment Arm C
Placebo Comparator
Placebo for 96 weeks
干预措施: Placebo (Biological)
Treatment Arm A
Experimental
Simtuzumab 75 mg for 96 weeks
干预措施: Simtuzumab (Biological)
Treatment Arm B
Experimental
Simtuzumab 125 mg for 96 weeks
干预措施: Simtuzumab (Biological)
结局指标
主要结局
Change From Baseline in MQC on Liver Biopsy at Week 96
时间窗: Baseline; Week 96
次要结局
- Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event(First dose date up to Week 96)
- Study Drug Exposure(First dose date up to Week 96)
- Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality(First dose date up to Week 96 plus 30 days)
研究者
研究点 (148)
Loading locations...
相似试验
终止
2 期
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisNCT01769196Gilead Sciences544
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic AdenocarcinomaPancreatic CancerNCT01472198Gilead Sciences250
终止
2 期
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01513317Janssen Research & Development, LLC76
已完成
2 期
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisMyelofibrosisNCT01369498Gilead Sciences54
终止
2 期
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)Lupus NephritisNCT05781750Kezar Life Sciences, Inc.84